106147-84-6

Basic information

• Product Name: (5-Methyl-1-trityl-1H-iMidazol-4-yl)Methanol
• Synonyms: (5-Methyl-1-trityl-1H-iMidazol-4-yl)Methanol;1H-IMidazole-4-Methanol, 5-Methyl-1-(triphenylMethyl)-
• CAS NO: 106147-84-6
• Molecular Formula: C₂₄H₂₂N₂O
• Molecular Weight: 354.44428
• Mol File: 106147-84-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (5-Methyl-1-trityl-1H-iMidazol-4-yl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (5-Methyl-1-trityl-1H-iMidazol-4-yl)Methanol(106147-84-6)
• EPA Substance Registry System: (5-Methyl-1-trityl-1H-iMidazol-4-yl)Methanol(106147-84-6)

Safety Data

• Hazardous Substances Data: 106147-84-6(Hazardous Substances Data)

Usage

General Description

"(5-Methyl-1-trityl-1H-iMidazol-4-yl)Methanol" is a unique chemical compound with an interesting name that relates to the specific structure and characteristics of the molecule. The name suggests that the molecule has an imidazole ring, a common structure found in many important biological molecules. This five-membered ring system is present in key biomolecules, such as histidine and the B-group vitamin biotin. The compound is a derivate of imidazole, possessing a methyl group at the 5th position and a trityl group at the 1st position, enhancing its organic nature. There is also a methanol group attached, perhaps giving it solubility in certain solvents. However, detailed information about its properties, uses or biological effects is not readily available, suggesting that it might be a compound synthesized and used largely for research purposes.

Upstream product

• 76-83-5 trityl chloride 
• 29636-87-1 4⁽⁵⁾-methyl-5⁽⁴⁾-hydroxymethylimidazole 
• 38585-62-5 4-hydroxymethyl-5-methylimidazole hydrochloride 
• 7487-88-9 magnesium sulfate 

Downstream Products

• 106147-86-8 4-(2,2-diphenylethyl)-5-methyl-1-tritylimidazole 
• 106147-59-5 4⁽⁵⁾-(2,2-diphenylethyl)-5⁽⁴⁾-methylimidazole 
• 698353-90-1 (2S,4E)-5-[5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl]-2-[[(phenylmethoxy)carbonyl]amino]-4-pentenoic acid 1,1-dimethylethyl ester 
• 500782-76-3 C₂₈H₄₁N₅O₄ 
• 500782-75-2 C₄₇H₅₅N₅O₄ 
• 500782-74-1 C₄₇H₄₆N₄O₃ 
• 501010-05-5 C₂₄H₃₃N₅O₄ 
• 500783-14-2 C₄₃H₄₇N₅O₄ 
• 501010-23-7 C₂₄H₃₃N₅O₄ 
• 500783-08-4 C₄₃H₄₇N₅O₄ 
• 501010-21-5 C₂₄H₃₂FN₅O₄ 
• 500783-06-2 C₄₃H₄₆FN₅O₄ 
• 500783-04-0 C₄₇H₄₉N₅O₄ 
• 500783-02-8 C₃₅H₃₄N₄O 

Relevant articles and documents

Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I

A series of compounds based on the carboxyl-terminal CAAL sequence of PGGTase-I substrates was designed and synthesized. Using piperazin-2-one as a semi-rigid scaffold, we have introduced critical pharmacophores in a well-defined arrangement to mimic the CAAL sequence. High potency and exceptional selectivity were obtained for inhibition of PGGTase-I with structures such as 45 and 70. Potency of this series of GGTIs was dependent on the presence of an l-leucine residue with a free carboxyl terminus, as well as an S configuration of the 3-aryl group. The selectivity was significantly enhanced by 5-methyl substitution on the imidazole ring and fluorine substitution on the 3-aryl group. Modification of the 6-position of the piperazinone scaffold was found to be unfavorable. Compounds 44 and 69, the corresponding methyl esters of 45 and 70, were found to selectively block processing of Rap1A by PGGTase-I in whole cells with IC50 values of 0.4 M and 0.7 M respectively. The Royal Society of Chemistry 2006.

Quinoxaline derivatives useful in therapy

Compounds of formula (I), wherein A represents N or CH; R1 and R2 independently represent C1-4 alkyl, halo or CF3 ; R3 represents C1-4 alkyl (optionally substituted), C3-7 cycloa

Substituted 1H-imidazoles

New substituted 1H-imidazoles and their salts, processes for the preparation thereof and pharmaceutical compositions. These compounds have the formula STR1 wherein R1, R2, R3 and R5 =hydrogen or C1 -C4 -alkyl; R4 =hydrogen, C1 -C4 -alkyl or C1 -C4 -alkoxy; Y1 =hydrogen and Y2 =OZ2 or the reverse; Z1 =Z2 =hydrogen or C1 -C4 -alkyl or Z1 and Z2 =--CH2 -- or --C(CH3)2 --. These compounds are prepared either by reducing a corresponding imidazole compound having a hydroxyl or alkoxy group on the methyl bridge between the imidazole and phenyl rings, or by hydrolyzing a 4-[[2,2-dimethyl-4H-1,3-benzodioxin-6(or 8)-yl]methyl]-1H-imidazole, or yet by reducing an alkyl 3-[(1H-imidazol-4-yl)methyl]-2-hydroxybenzoate. These compounds have cardiac, cerebral and tissular anti-ischemic activities.